Trial Profile
A phase Ib/IIb, open-label, multi-center study of oral Panobinostat (LBH589) administered with 5-Azacitidine (Vidaza) in adult patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Azacitidine
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 05 Dec 2019 This trial has been discontinued in United Kingdom as per EudraCT record.
- 29 Oct 2019 Status changed from active, no longer recruiting to completed.
- 18 May 2019 This trial has been discontinued in Germany.